Clinical Research Directory
Browse clinical research sites, groups, and studies.
Sarcoma With EWSR1/FUS : POU2AF3 (COLCA2) Fusion : Molecular and Clinicopathologic Characterization of a Case Series.
Sponsor: University Hospital, Strasbourg, France
Summary
Sarcomas with the EWSR1/FUS :: POU2AF3 (COLCA2) fusion transcript represent a new molecularly defined entity, first described in 2023 (1). There are 24 cases reported in the literature, including 3 descriptive series totaling 19 cases (1-3). Clinically, this is an aggressive entity affecting patients of varying ages (16-74 years), most commonly located in the sinonasal tract, and capable of involving both bone and soft tissue. A few extrasinonasal cases have also been reported. Histologically, two morphological groups have been described (3): the first group (the rarest) is characterized by a low-grade morphology with non-atypical spindle cells; the second group is morphologically high-grade, featuring spindle, round, or epithelioid cells and possible divergent differentiation (epithelial, neuroendocrine, striated muscle, or bone). The immunophenotype of these lesions is nonspecific, with variable positivity for various markers such as S100, CD99, AE1/3, CD56, chromogranin, synaptophysin, SATB2, CD117, GFAP, and EMA. Given the clinical, morphological, and immunohistochemical features of this entity, numerous differential diagnoses can be considered: synovial sarcoma, malignant tumor of the peripheral nerve sheaths, Ewing sarcoma, myoepithelial tumor, biphenotypic sinonasal sarcoma, etc.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
10
Start Date
2026-11-15
Completion Date
2027-10-15
Last Updated
2026-11-16
Healthy Volunteers
No
Conditions
Interventions
methylation profiling
methylation profiling